Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCHWARTZ NORMAN D

(Last)

(First)

(Middle)

C/O BIO-RAD LABORATORIES, INC.

1000 ALFRED NOBEL DRIVE

(Street)

HERCULES

94547

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIOB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
Chairman, President, and CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/01/2023

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Bio-Rad B Common Stock	11/01/2023		M		35,000	A	$119.8	380,300	D
Bio-Rad B Common Stock	11/01/2023		F		25,642	D	$273	354,658	D
Bio-Rad B Common Stock	11/01/2023		M		16,000	A	$139.56	370,658	D
Bio-Rad B Common Stock	11/01/2023		F		12,274	D	$273	358,384	D
Bio-Rad B Common Stock	11/01/2023		M		15,000	A	$159.32	373,384	D
Bio-Rad B Common Stock	11/01/2023		F		12,024	D	$273	361,360	D
Bio-Rad B Common Stock								12,900	I	By Spouse⁽¹⁾
Bio-Rad B Common Stock								4,060,054	I	By Blue Raven Partners, L.P.⁽²⁾
Bio-Rad A Common Stock								432,920	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option (right to buy)	$119.8	11/01/2023		M			35,000	⁽³⁾	09/10/2024	Bio-Rad B Common Stock	35,000	$0	0	D
Non-Qualified Stock Option (right to buy)	$139.56	11/01/2023		M			16,000	⁽⁴⁾	09/11/2025	Bio-Rad B Common Stock	16,000	$0	0	D
Non-Qualified Stock Option (right to buy)	$159.32	11/01/2023		M			15,000	⁽⁵⁾	09/07/2026	Bio-Rad B Common Stock	15,000	$0	0	D

Explanation of Responses:

1. The reporting person disclaims beneficial ownership of these shares.

2. The shares are held by a limited partnership of which the reporting person is a limited and general partner. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

3. The option, representing a right to purchase a total of 35,000 shares, became exercisable in five equal annual installments beginning on September 10, 2015, which was the first anniversary of the date on which the option was granted.

4. The option, representing a right to purchase a total of 16,000 shares, became exercisable in five equal annual installments beginning on September 11, 2016, which was the first anniversary of the date on which the option was granted.

5. The option, representing a right to purchase a total of 15,000 shares, became exercisable in five equal annual installments beginning on September 7, 2017, which was the first anniversary of the date on which the option was granted.

	/s/ Norman Schwartz	11/02/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.